Published: Sat, January 13, 2018
Business | By Tara Barton

Gilead Sciences (NASDAQ:GILD) Rating Lowered to Neutral at Credit Suisse Group

West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company's stock worth $330,000 after purchasing an additional 32 shares in the last quarter. Gilead Sciences Inc (Call) now has $103.61 billion valuation.

The stock increased 0.44% or $0.35 during the last trading session, reaching $79.06. The company had a trading volume of 6,370,000 shares, compared to its average volume of 8,150,000. (NASDAQ:GILD) shares can stay above the price resistance around $79.87 a share, that could help propel Gilead Sciences, Inc. It has underperformed by 38.50% the S&P500. Insiders sold a total of 461,666 shares of company stock valued at $34,072,567 in the last three months. The hedge fund run by Alexander Medina Seaver held 867,360 shares of the property-casualty insurers company at the end of 2017Q3, valued at $14.14M, up from 243,782 at the end of the previous reported quarter. About 382,236 shares traded. (NASDAQ:UIHC) has declined 9.79% since January 12, 2017 and is downtrending. It has underperformed by 0.20% the S&P500. About 2.93M shares traded.

Since December 15, 2017, it had 2 buys, and 0 insider sales for $41,661 activity. Alton Gregg H had sold 25,000 shares worth $2.07M. Leerink Swann raised their price target on Gilead Sciences from $84.00 to $85.00 and gave the company a "market perform" rating in a research note on Thursday, October 19th. Meyers James R sold $4.99 million worth of stock or 60,000 shares. Gilead Sciences makes up 1.9% of Shelter Mutual Insurance Co's investment portfolio, making the stock its 27th largest holding. (NASDAQ:GILD) to report earnings on February, 6. During the same period past year, the firm earned $2.75 earnings per share. The company has a market cap of $88.05 billion, a P/E ratio of 6.18 and a beta of 1.11. The business's revenue was down 13.2% on a year-over-year basis. equities analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current year. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Finally, BMO Capital Markets dropped their target price on Gilead Sciences from $89.00 to $83.00 and set an "outperform" rating for the company in a research report on Friday, October 27th.

Ken Stern & Associates Inc. Has $920000 Holdings in QUALCOMM, Inc. (QCOM)
The stock of General Electric Company (NYSE:GE) has "Buy" rating given on Friday, September 15 by RBC Capital Markets. The stock of QUALCOMM Incorporated (NASDAQ:QCOM) has "Neutral" rating given on Wednesday, December 14 by JP Morgan.

OTC Markets Group Inc. operates financial markets for the United States and worldwide securities. (NASDAQ:AAPL), 40 have Buy rating, 1 Sell and 11 Hold. Canaccord Genuity has "Buy" rating and $180.0 target. The rating was upgraded by Maxim Group to "Buy" on Thursday, November 30. (NASDAQ:AAPL) on Wednesday, August 2 with "Buy" rating. As per Wednesday, February 3, the company rating was maintained by Piper Jaffray. The company was initiated on Thursday, August 31 by William Blair. The firm has "Buy" rating by Berenberg given on Monday, September 12. (NASDAQ:UIHC) rating on Wednesday, September 20.

Investors sentiment decreased to 1.17 in Q3 2017. Its up 0.02, from 0.68 in 2017Q2. It increased, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.13 by $0.14. Sunbelt Securities invested in 0.61% or 7,150 shares. Cohen Lawrence B accumulated 39,618 shares.

Gilead Sciences, Inc. has a current ratio of 3.7, indicating whether the company's short-term assets (cash, cash equivalents, marketable securities, receivables and inventory) are readily obtainable to pay off its short-term liabilities. It also increased its holding in Archer Daniels Midland Co (NYSE:ADM) by 53,275 shares in the quarter, for a total of 865,126 shares, and has risen its stake in Maxim Integrated Prods Inc (NASDAQ:MXIM). (NASDAQ:GILD). Putnam Invs owns 4.48M shares or 0.84% of their United States portfolio. Waddell & Reed Financial Inc accumulated 860,100 shares or 0.15% of the stock. Northwestern Mutual Wealth Management reported 0.05% in Gilead Sciences, Inc. Cubist Systematic Strategies Ltd has 0.1% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Proshare Advsr Ltd Liability Corporation has 0.72% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Ghp Advsrs holds 0.06% or 4,990 shares in its portfolio. Caxton Associate LP holds 0.01% or 600 shares. Trust Department Mb National Bank N A, Illinois-based fund reported 71,904 shares. This simple numeric scale reads 1 to 5, and it changes brokerage firm Moderate Sell recommendations into an average broker rating. Therefore 33% are positive. Northwest Inv Counselors has 0.03% invested in Gilead Sciences, Inc. (NASDAQ:REGN) has "Equal Weight" rating given on Wednesday, August 5 by Barclays Capital. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. They issued an "outperform" rating and a $94.00 price objective on the stock. The firm earned "Buy" rating on Friday, June 30 by FBR Capital. Investors may use Price to Book to display how the market portrays the value of a stock. Its the same as in 2017Q2. (NASDAQ:REGN). Ithaka owns 3.3% invested in Regeneron Pharmaceuticals, Inc. 130,443 were accumulated by Goldman Sachs Grp Inc Inc. Manning And Napier Ltd Liability holds 189,381 shares. Investors of record on Friday, December 15th were given a $0.52 dividend. (NYSE:TOWR). Campbell Comm Adviser Limited Liability Corp holds 0.18% or 8,230 shares in its portfolio. Motco, Texas-based fund reported 494 shares. Ngam Limited Partnership invested in 0.13% or 146,516 shares. British Columbia invested 0.03% in Mercadolibre, Inc. (NYSE:GTN). Envestnet Asset invested 0% of its portfolio in Gray Television, Inc. Intact Investment Inc has invested 0.01% in Gilead Sciences, Inc.

Like this: